Patient characteristics
. | GM-CSF priming . | No priming . | Total . |
---|---|---|---|
Patients | 25 | 28 | 53 |
Sex | |||
Male | 18 | 19 | 37 |
Female | 7 | 9 | 16 |
Age | |||
Median | 46 | 46.5 | 46 |
Range | 24-72 | 34-63 | 24-72 |
Karnofsky performance status | |||
100 | 12 | 8 | 20 |
90 | 9 | 13 | 22 |
80 | 2 | 6 | 8 |
70 | 2 | 1 | 3 |
Diagnosis | |||
Renal cell carcinoma | 12 | 13 | 25 |
Melanoma | 13 | 15 | 28 |
Prior therapy | |||
Chemotherapy (low dose) | 5 | 4 | 9 |
Immunotherapy | 11 | 19 | 30 |
Hormonal therapy | 1 | 0 | 1 |
Radiation therapy | 6 | 4 | 10 |
None | 11 | 9 | 2 |
. | GM-CSF priming . | No priming . | Total . |
---|---|---|---|
Patients | 25 | 28 | 53 |
Sex | |||
Male | 18 | 19 | 37 |
Female | 7 | 9 | 16 |
Age | |||
Median | 46 | 46.5 | 46 |
Range | 24-72 | 34-63 | 24-72 |
Karnofsky performance status | |||
100 | 12 | 8 | 20 |
90 | 9 | 13 | 22 |
80 | 2 | 6 | 8 |
70 | 2 | 1 | 3 |
Diagnosis | |||
Renal cell carcinoma | 12 | 13 | 25 |
Melanoma | 13 | 15 | 28 |
Prior therapy | |||
Chemotherapy (low dose) | 5 | 4 | 9 |
Immunotherapy | 11 | 19 | 30 |
Hormonal therapy | 1 | 0 | 1 |
Radiation therapy | 6 | 4 | 10 |
None | 11 | 9 | 2 |